{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-1/diagnosis/diagnosis-adults/","result":{"pageContext":{"chapter":{"id":"4f5a4b78-cd62-5755-89da-ec0cde4a8f1b","slug":"diagnosis-adults","fullItemName":"Diagnosis - adults","depth":2,"htmlHeader":"<!-- begin field bef092fd-43fa-44ea-8c7b-bbf37ef60f45 --><h2>How should I diagnose type 1 diabetes in an adult?</h2><!-- end field bef092fd-43fa-44ea-8c7b-bbf37ef60f45 -->","summary":"","htmlStringContent":"<!-- begin item a562f36f-2078-43ff-b92e-58b3d8e3dbe2 --><!-- begin field dd816ae3-98b8-49be-aa4b-d1ec669d7bb2 --><ul><li><strong>Diagnose type 1 diabetes</strong> <strong>on clinical grounds in adults presenting with hyperglycaemia </strong><strong>(random plasma glucose more than 11 mmol/L)</strong><strong>, bearing in mind that adults with type 1 diabetes typically (but do not always) have one or more of the following:</strong><ul><li>Ketosis.</li><li>Rapid weight loss.</li><li>Age of onset younger than 50 years.</li><li>Body mass index (BMI) below 25 kg/m<sup>2</sup>.</li><li>Personal and/or family history of autoimmune disease.</li></ul></li><li><strong>Do not discount a diagnosis of type 1 diabetes if an adult presents with</strong> a BMI of 25 kg/m<sup>2</sup> or above, or is aged 50 years or older. </li><li><strong>If type 1 diabetes is diagnosed, </strong>refer the person immediately (on the same day) to a diabetes specialist team to confirm the diagnosis and provide immediate care.</li><li><strong>Do not routinely m</strong><strong>easure</strong> <strong>C-peptide and/or diabetes-specific autoantibody titres</strong> <strong>to confirm the diagnosis of type 1 diabetes.</strong><ul><li>C-peptide and/or diabetes-specific autoantibody titres may be measured (usually in secondary care) if:<ul><li>Type 1 diabetes is suspected but the clinical presentation includes some atypical features (for example age 50 years or older, BMI of 25 kg/m<sup>2</sup> or above, or slow evolution of hyperglycaemia), <em>or</em></li><li>Type 1 diabetes has been diagnosed and treatment started but there is a clinical suspicion that the person may have a monogenic form of diabetes, and one or both tests may guide the use of genetic testing, <em>or </em></li><li>Classification of diabetes is uncertain and confirming type 1 diabetes would have implications for availability of treatment, for example continuous subcutaneous insulin infusion (CSII or 'insulin pump') therapy. </li></ul></li></ul></li></ul><!-- end field dd816ae3-98b8-49be-aa4b-d1ec669d7bb2 --><!-- end item a562f36f-2078-43ff-b92e-58b3d8e3dbe2 -->","topic":{"id":"e0026a38-6f9d-5508-9a1c-f9cb4d041950","topicId":"83d7e1f3-89ef-4bb8-9e6c-8f19b4d34e87","topicName":"Diabetes - type 1","slug":"diabetes-type-1","lastRevised":"Last revised in November 2020","chapters":[{"id":"d661aaf0-a104-5e58-84d5-4a2a8a0f4f5d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4c43c028-bb33-5fef-9faa-b1109c46c86c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0b467f1-8df4-5e16-b575-6586d482ff25","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3b6f1413-616a-5f8a-bdb2-5039d4c9da3d","slug":"changes","fullItemName":"Changes"},{"id":"c85ea3eb-a714-591e-9173-893969e82b38","slug":"update","fullItemName":"Update"}]},{"id":"5c1743f6-3cac-5ff9-adaf-cb4e0825d600","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"87ced251-ae95-56bb-af77-2ff4fed8e622","slug":"goals","fullItemName":"Goals"},{"id":"65dfcd12-0085-5a25-bb44-e3c6fc31638d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5062125f-ab58-5026-aaff-b6b85d231c1c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8599fb5-b011-56d3-a366-6cf800a0fefa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8c093980-e55d-5ca2-b0b5-b2f4510c1c97","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9c0a7c64-7734-5a4a-83ed-b90c2c0bbe1c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d65f3cd5-05c6-5a1e-9944-451040c15857","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d43fa19c-c0e0-573b-b397-39d8c6688f93","slug":"definition","fullItemName":"Definition"},{"id":"8a652055-2d88-550f-8db1-ae8e33b071bd","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"90b285f5-e373-561a-826a-e61feb7838dd","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"9cae1d9c-e58a-549e-90b2-2d2cadc11677","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6923a3e8-0ad7-53c5-995c-b35c22158c20","slug":"complications","fullItemName":"Complications"}]},{"id":"a8fd4233-8b09-576a-b7a0-7f8ceeb4bdc8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4f5a4b78-cd62-5755-89da-ec0cde4a8f1b","slug":"diagnosis-adults","fullItemName":"Diagnosis - adults"},{"id":"6f5d18f4-c26e-5580-956a-03c18359bca5","slug":"diagnosis-children-young-people","fullItemName":"Diagnosis - children and young people"},{"id":"325f4df9-1bb2-5a87-a070-e07935161353","slug":"when-to-suspect-diabetic-ketoacidosis","fullItemName":"When to suspect diabetic ketoacidosis"},{"id":"2a892a37-ec75-5c0c-b79d-9b550ba6f44a","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"ef2fcfd0-0be0-5051-a142-f33f073f8866","fullItemName":"Management","slug":"management","subChapters":[{"id":"18ccffe2-a6f3-577e-91e5-cb4155aa3217","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"e6d0bbff-43a3-5fba-bff0-2be7be288c52","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"23697cf0-b89b-5f73-af63-48585cfa9295","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"15bdab2b-50dc-5e17-9f62-653119d307ca","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bc8c7324-ac1b-5655-93c6-4b5346239433","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"1558081d-ff31-5041-982a-0995ddcdac09","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6ce82109-660d-58c4-8f94-f3daf311c5a8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59ae6a38-016e-5016-8cee-931384eb78b4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"03942c19-0b79-5891-a48e-fc314241de96","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f415e38-eb27-5fde-8084-57d74c402a7c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a8fd4233-8b09-576a-b7a0-7f8ceeb4bdc8","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"ef562c95-2af7-5dde-9570-6f90f5b90df6","slug":"basis-for-recommendation-dc8","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 96e4c1d7-9084-4c9e-93dc-a176aefdf48a --><h3>Basis for recommendation</h3><!-- end field 96e4c1d7-9084-4c9e-93dc-a176aefdf48a -->","summary":null,"htmlStringContent":"<!-- begin item dc867ed2-8a67-42a0-84a9-269548633723 --><!-- begin field d8126159-28dd-474a-a44f-d72f2df112d1 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-1/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-1/references/\">NICE, 2016d</a>]. The basis for the NICE recommendations have been briefly summarized in this section. For detailed information on the evidence NICE used to make these recommendations, see the <a href=\"https://www.nice.org.uk/guidance/ng17/evidence/full-guideline-pdf-435400241\" data-hyperlink-id=\"a0d1b875-3dbe-4208-addb-a93100984c4b\">full NICE guideline</a>.</p><h4>Clinical features of type 1 diabetes in adults</h4><ul><li>The clinical features of type 1 diabetes are based on the expert opinion and clinical experience of the NICE guideline development group (GDG).</li></ul><h4>Diagnosis of type 1 diabetes in adults</h4><ul><li>The NICE guideline states that the diagnosis of type 1 diabetes in adults should largely be made on clinical grounds, taking into account the presence of the typical features of the condition but bearing in mind that these features are not always present.</li><li>Although NICE did not specifically review the evidence for this recommendation, data known to the GDG suggests a 2% misdiagnosis rate when the diagnosis of type 1 diabetes is made on clinical grounds. </li></ul><h4>Immediate (same-day) referral for all adults diagnosed with type 1 diabetes</h4><ul><li>NICE does not make any recommendations on how soon after diagnosis the person should be referred to the diabetes team, but states that people with type 1 diabetes should receive insulin treatment at an appropriate time to prevent the immediate complication of diabetic ketoacidosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-1/references/\">NICE, 2015a</a>].</li><li>The recommendation to refer the person immediately (on the same day) to a diabetes specialist team is extrapolated from the NICE guideline <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management</em>, which recommends immediate referral to a paediatric specialist diabetes team for confirmation of diagnosis and provision of immediate care for children and young people with suspected type 1 diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-1/references/\">NICE, 2016e</a>].</li></ul><h4>Measuring C-peptide and/or diabetes-specific autoantibody titres</h4><ul><li>The NICE GDG recognized that there may be occasions where additional tests are needed, for example to confirm a diagnosis of type 1 diabetes when a clinical feature is atypical or when the classification of the type of diabetes is uncertain. </li><li>Following a review of the available evidence (which was graded as low quality), the GDG concluded that no single test could reliably confirm or refute the diagnosis of type 1 diabetes and that no single test was of sufficient predictive accuracy to reliably classify the types of diabetes.</li><li>Based on the evidence and the very low rate of misdiagnosis using clinical features alone, the GDG believed it would be inappropriate to use C-peptide and/or diabetes-specific autoantibody titres in all people with newly diagnosed diabetes, as incorrect conclusions might be drawn from them. However, for people in whom there is uncertainty about the classification of diabetes type, particularly if this might lead to a change in treatment, these tests may be useful, although they must be interpreted in the context of the clinical picture. </li><li>The GDG advised that where the tests are used, it is necessary to consider timing, as the predictive value of the tests to support a diagnosis of type 1 diabetes changes with increasing time from presentation with diabetes.</li></ul><!-- end field d8126159-28dd-474a-a44f-d72f2df112d1 --><!-- end item dc867ed2-8a67-42a0-84a9-269548633723 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}